Acorda Therapeutics — Q1 2023 Earnings Presentation
20 slides from Acorda Therapeutics's earnings presentation, May 11, 2023
Slide 1: Acorda Therapeutics 2023 Q1 Earnings Call
Acorda Therapeutics 2023 Q1 Earnings Call May 11, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncerta
Slide 3: Inbrija
ng capsules
Slide 4: INBRIJA U.S. Net Sales – Q1 2023
INBRIJA U.S. Net Sales – Q1 2023 $5.6M Q1 2023 net revenue 52% increase vs Q1 2022 4 2023 Q1 EARNINGS
Slide 5: INBRIJA U.S. Trends Since Launch
INBRIJA U.S. Trends Since Launch Net Sales $M 12.0 52%> vs Q1 22 10.0 10.4 9.4 9.0 8.0 7.8 7.6 7.9 6.0 6.8 6.4 6.1 5.6 4.0 5.0 4.7 5.0 4.4 3.7 2.0 3.0 0.0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2021 2022 2023 5 2023 Q1 EARNINGS
Slide 6: INBRIJA Trends Since Launch (TRX)
INBRIJA Trends Since Launch TRX $M 4000 11%> vs Q1 22 3500 3793 3464 3546 3000 3361 3319 3249 3300 3110 3070 3125 3077 2992 2995 2500 2817 2761 2000 1915 1500 1000 500 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2021 2022 6 2023 Q1 EARNINGS
Slide 7: INBRIJA Trends Since Launch: Cartons Dispensed
INBRIJA Trends Since Launch Cartons Dispensed to Patients $M 12%> vs Q1 22 12000 10000 11029 10135 9924 10102 9528 9349 8000 8883 8737 9087 8514 8305 7857 7839 6000 6909 6955 4000 4198 2000 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2020 2021 2022 2023 7 2023 Q1 EARNINGS
Slide 8: INBRIJA TV Commercial Launched on Streaming Services
INBRIJA TV Commercial Launched on Streaming Services Launched in April for Parkinson’s www.GetInbrija.com Awareness Month Airing on ~50 streaming services Paramount+, Hulu, Disney Digital “surround sound” campaign 2.5 M views in six weeks Viewed by 40% of targeted HCPs 8 2023 Q1 EARNINGS
Slide 9: Agreement with Hangzhou Chance Pharmaceuticals for China
Agreement with Hangzhou Chance Pharmaceuticals for China Up-front payment of $2.5 million Near term milestones of up to $6 million Regulatory approval payment of $3 million Additional sales milestones of up to $132.5 million Fixed fee for each carton of Inbrija to China PD population in China estima
Slide 10: Ampyra
Ampyra ® 10 2023 Q1 EARNINGS 10
Slide 11: AMPYRA U.S. Net Sales – Q1 2023
AMPYRA U.S. Net Sales – Q1 2023 $12.6M Q1 2023 net revenue 15% decrease vs Q1 2022 11 2023 Q1 EARNINGS
Slide 12: Maintaining Branded AMPYRA
Maintaining Branded AMPYRA Net Sales, $MM $50.0 $44.2 $45.0 $40.6 $40.8 $40.0 $37.6 $35.0 $30.0 $27.2 $25.8 $25.3 $25.0 $21.8 $22.5 $20.3 $20.0 $21.1 $19.9 $18.8 $20.0 $18.2 $14.9 $15.0 $12.6 $10.0 $5.0 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2019 2020 2021 2022 2023 12 2023 Q1 EARNING
Slide 13: Maintaining Branded AMPYRA
Maintaining Branded AMPYRA Annual net sales expected to stabilize at $60+M / year Field team continues to promote the brand ~200 HCPs resumed prescribing of AMPYRA in 2022 Physician and patient brand loyalty has helped to maintain access ~70% of all covered lives have access to AMPYRA1 1 MMIT Nation
Slide 14: Financials
Financials 14 2023 Q1 EARNINGS
Slide 15: Financial Summary
2022 Financial Summary ∆ ($ in millions) 1Q’23 1Q’22 Q/Q Net Global Inbrija Revenue 6.1 3.7 64.9% Net Ampyra Revenue 12.6 14.9 (15.4%) R&D 1.4 1.7 (17.6%) SG&A 22.5 26.9 (16.4%) GAAP Net (Loss) (16.8) (24.5) (31.4%) Cash, Cash Equivalents and 37.8 51.5 (26.6%) Restricted Cash ACOR 2014 third Quarter
Slide 16: Q1 2023 Ex-U.S. Revenue
Q1 2023 Ex-U.S. Revenue INBRIJA ex-US $ 526K FAMPYRA Royalty $ 2.9M Neurelis Inc. Royalty $ 587K 16 2023 Q1 EARNINGS
Slide 17: 2023 Financial Guidance
2023 Financial Guidance INBRIJA U.S. Net Revenue $38M - $42M AMPYRA U.S. Net Revenue $65M - $70M Adjusted OpEx $93M - $103M Ending Cash Balance $43M - $47M 17 2023 Q1 EARNINGS
Slide 18: Board of Directors Update
Board of Directors Update Jeff Randall to step down in June 2023 – Served on Acorda’s board since 2006 – Chair of audit committee Tom Burns to stand for election at June annual shareholder meeting – CFO of XOMA Corporation – 25 years of finance experience in biotech and high tech 18 2023 Q1 EARNINGS
Slide 19: 2023 Priorities to Build Shareholder Value
2023 Priorities to Build Shareholder Value Accelerate INBRIJA trajectory -Additional ex-US INBRIJA agreements Maintain AMPYRA Continued fiscal discipline -Cash flow positive 2023 ARCUS collaborations 19 2023 Q1 EARNINGS
Slide 20: LIFE.
LIFE. SCIENCE. °